News - OxyDial Inc

Jan 28 2026

Diabetes Drug to be Tested for Sickle Cell Kidney Protection

Researchers at the University of Illinois Chicago, have received a $3.78 million federal grant to study whether empagliflozin, a diabetes medication, can slow kidney damage in people with sickle cell …

OxyDial

Jan 20 2026

Repurposed Alzheimer’s Drug Emerges as a Potential Game-Changer for Sickle Cell Anemia

An international research team led by the University of Zurich has published promising Phase II data for memantine, a long-approved, off-patent Alzheimer’s drug produced by AbbVie, in the treatment of …

OxyDial

Jan 13 2026

HUTCHMED’s Sovleplenib Moves Closer to a First-in-Class Treatment for Warm Autoimmune Hemolytic Anemia

New Phase 3 data released by HUTCHMED from the China-based ESLIM-02 trial shows that sovleplenib achieved a durable hemoglobin response in patients with warm antibody autoimmune hemolytic anemia (wAIHA), a …

OxyDial

Jan 6 2026

Ayrmid Demonstrates Motixafortide’s Potential to Unlock Gene Therapy Access for Sickle Cell Disease

New data presented by AyrmidPharma at #ASH2025 indicates that motixafortide (APHEXDA®) can robustly mobilize the hematopoietic stem cells (HSCs) required for gene therapies in sickle cell disease (SCD). The Phase …

OxyDial

Jan 2 2026

Agios’ AQVESME™ (mitapivat) Receives FDA Approval for Anemia in Thalassemia

The U.S. FDA has approved Agios Pharmaceuticals‘ AQVESME™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. This approval, based on the positive Phase 3 ENERGIZE and …

OxyDial

Dec 29 2025

High-Dose Pociredir Data Show Stronger HbF Responses in Sickle Cell Disease

New Phase 1b data from Fulcrum Therapeutics suggest that higher doses of the investigational oral therapy pociredir may offer greater benefits for adults with sickle cell disease (SCD). In the …

OxyDial

Dec 18 2025

Motixafortide Data Points to More Accessible Gene Therapy Pathways in SCD

New clinical data from Ayrmid highlight a promising advance in stem cell mobilization for people with SCD pursuing gene therapy. In a first-in-human trial, the CXCR4 inhibitor motixafortide, alone and …

OxyDial

Dec 11 2025

Transdermal Curcumin Gel Shows Potential to Improve Cardiac Health in SCD Preclinical Study

New laboratory research from Vascarta Inc. highlights a novel approach to addressing SCD complications. The company’s investigational skin gel, VAS‑101, which contains the turmeric-derived compound curcumin, partially restored mitochondrial function …

OxyDial

Dec 5 2025

Novartis to Present Robust Hematology and Oncology Portfolio at Key Medical Conferences

Novartis announced it will present data from over 70 abstracts at the upcoming American Society of Hematology (ASH) Annual Meeting and San Antonio Breast Cancer Symposium (SABCS). Key highlights include …